Trachoma and antibiotic use: the ’A‘ in SAFE

References

• Resnikoff S, Pascolini D, Etya’ale D et al. Global data on visual impairment in the year 2002. Bull. World Health Organ.82, 844–851 (2004).
   PubMed Web of Science ®Google Scholar
• World Health Organization. WHA51.11 World Health Assembly (Ed.) (1998).
   Google Scholar
• Mariotti S, Pascolini D, Rose-nussbaumer J. Trachoma: global magnitude of a preventable cause of blindness. Br. J. Ophthalmol.93, 563–568 (2009).
   PubMed Web of Science ®Google Scholar
• Frick KD, Hanson CL, Jacobson GA. Global burden of trachoma and economics of the disease. Am. J. Trop. Med. Hyg.69, 1–10 (2003).
   PubMed Web of Science ®Google Scholar
• Courtright P, Sheppard J, Lane S, Sadek A, Schachter J, Dawson CR. Latrine ownership as a protective factor in inflammatory trachoma in Egypt. Br. J. Ophthalmol.75, 322–325 (1991).
   PubMed Web of Science ®Google Scholar
• West SK, Munoz B, Turner VM, Mmbaga BBO, Taylor HR. The epidemiology of trachoma in Central Tanzania. Int. J. Epidemiol.20, 1088–1092 (1991).
   PubMed Web of Science ®Google Scholar
• Katz J, Zeger S, Tielsch L. Village and household clustering of xerophthalmia and trachoma. Int. J. Epidemiol.17, 865–869 (1988).
   PubMed Web of Science ®Google Scholar
• Blake IM, Burton MJ, Bailey RL et al. Estimating household and community transmission of ocular Chlamydia trachomatis. PLoS Negl. Trop. Dis.3, e401 (2009).
   Google Scholar
• Bailey R, Osmond C, Mabey DC, Whittle HC, Ward ME. Analysis of the household distribution of trachoma in a Gambian village using a Monte Carlo simulation procedure. Int. J. Epidemiol.18, 944–951 (1989).
   PubMed Web of Science ®Google Scholar
• West SK, Bailey R. Trachoma. In: The Epidemiology of Eye Disease. Johnson GJ, Minassian DC, Weale RA, West SK (Eds), Arnold, London, UK, 164–185 (2003).
   Google Scholar
• Grayston J, Yeh L, Kuo C. Importance of reinfection in the pathogenesis of trachoma. Rev. Infect. Dis.7, 717–725 (1985).
   PubMedGoogle Scholar
• Taylor HR, Johnson SL, Prendergast RA, Schachter J, Dawson CR, Silverstein AM. An animal model of trachoma: the importance of repeated reinfection. Invest. Ophthalmol. Vis. Sci.23, 507–515 (1982).
   PubMed Web of Science ®Google Scholar
• Reinhards JWA, Nižeti B, Kupka K, Maxwell-Lyons F. Studies on the epidemiology and control of seasonal conjunctivitis and trachoma in southern Morocco. Bull. World Health Organ.39, 497–545 (1968).
   PubMed Web of Science ®Google Scholar
• Muñoz B, Bobo L, Mkocha H, Lynch M, Hsieh YH, West S. Incidence of trichiasis in a cohort of women with and without scarring. Int. J. Epidemiol.28, 1167–1171 (1999).
   PubMed Web of Science ®Google Scholar
• Bernauer WBD, Wright P. Chronic progressive conjunctival cicatrisation. Eye7, 371–378 (1993).
   PubMed Web of Science ®Google Scholar
• Burton MJ, Bowman RJ, Faal H et al. Long term outcome of trichiasis surgery in the Gambia. Br. J. Ophthalmol.89, 575–579 (2005).
   PubMed Web of Science ®Google Scholar
• Thylefors B, Dawson C, Jones BR, West SK, Taylor HR. A simple system for the assessment of trachoma and its complications. Bull. World Health Organ.65, 477–483 (1987).
   PubMed Web of Science ®Google Scholar
• West ES, Munoz B, Mkocha H et al. Mass treatment and the effect on the load of Chlamydia trachomatis infection in a trachoma-hyperendemic community. Invest. Ophthalmol.Vis. Sci.46, 83–87 (2005).
   PubMed Web of Science ®Google Scholar
• Keenan JDLT, Alemayehu W, Melese M et al. Slow resolution of clinically active trachoma following successful mass antibiotic treatments. Arch. Ophthalmol.129, 512–513 (2011).
   PubMed Web of Science ®Google Scholar
• Burton MJ, Hu VH, Massae P et al. What is causing active trachoma? The role of nonchlamydial bacterial pathogens in a low prevalence setting. Invest. Ophthalmol. Vis. Sci.52(8), 6012–6017 (2011).
   PubMed Web of Science ®Google Scholar
• Ngondi J, Gebre T, Shargie EB et al. Evaluation of three years of the SAFE strategy (Surgery, Antibiotics, Facial cleanliness and Environmental improvement) for trachoma control in five districts of Ethiopia hyperendemic for trachoma. Trans. R. Soc. Trop. Med. Hyg.103(10), 1001–1010 (2009).
   PubMed Web of Science ®Google Scholar
• Ngondi J, Onsarigo A, Matthews F et al. Effect of 3 years of SAFE (surgery, antibiotics, facial cleanliness, and environmental change) strategy for trachoma control in southern Sudan: a cross-sectional study. Lancet368, 589–595 (2006).
   PubMed Web of Science ®Google Scholar
• Girard AEGD, English AR, Gootz TD et al. Pharmacokinetic and in vivo studies with azithromycin (CP-62,993), a new macrolide with an extended half-life and excellent tissue distribution. Antimicrob. Agents Chemother.12, 1948–1954 (1987).
   Google Scholar
• Huguet PBL, Einterz EM, Goldschmidt P, Bensaid P. Mass treatment of trachoma with azithromycin 1.5% eye drops in the Republic of Cameroon: feasibility, tolerance and effectiveness. Br. J. Ophthalmol.94, 157–160 (2010).
   PubMed Web of Science ®Google Scholar
• Schachter J, West SK, Mabey D et al. Azithromycin in control of trachoma. Lancet354, 630–635 (1999).
   PubMed Web of Science ®Google Scholar
• Bowman RJ, Sillah A, Van Dehn C et al. Operational comparison of single-dose azithromycin and topical tetracycline for trachoma. Invest. Ophthalmol. Vis. Sci.41, 4074–4079 (2000).
   PubMed Web of Science ®Google Scholar
• Taylor HR. Trachoma; a blinding scourge from the bronze age to the twenty first century (1st Edition), Center for Eye Research, Australia (2008).
   Google Scholar
• Evans JRSA. Antibiotics for trachoma. Cochrane Database Syst. Rev.3, CD001860 (2011).
   Google Scholar
• WHO Working Group. Report of the eighth meeting of the WHO alliance for the global elimination of blinding trachoma. World Health Organization, Geneva, Switzerland. WHO/PBD/GET/04.2 (2004).
   Google Scholar
• Solomon AW, Holland MJ, Alexander ND et al. Mass treatment with single-dose azithromycin for trachoma. N. Engl. J. Med.351, 1962–1971 (2004).
   PubMed Web of Science ®Google Scholar
• West SK, Munoz B, Mkocha H et al. Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study. Lancet366, 1296–1300 (2005).
   PubMed Web of Science ®Google Scholar
• Broman AT, Shum K, Munoz B, Duncan DD, West SK. Spatial clustering of ocular chlamydial infection over time following treatment, among households in a village in Tanzania. Invest. Ophthalmol. Vis. Sci.47, 99–104 (2006).
   PubMed Web of Science ®Google Scholar
• Lietman T, Porco T, Dawson C, Blower S. Global elimination of trachoma: how frequently should we administer mass chemotherapy? Nat. Med.5, 572–576 (1999).
   PubMed Web of Science ®Google Scholar
• Whitty CJ, Glasgow KW, Sadiq ST, Mabey DC, Bailey R. Impact of community-based mass treatment for trachoma with oral azithromycin on general morbidity in Gambian children. Pediatr. Infect. Dis. J.18, 955–958 (1999).
   PubMedGoogle Scholar
• Fry AM, Jha HC, Lietman TM et al. Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal. Clin. Infect. Dis.35, 395–402 (2002).
   PubMed Web of Science ®Google Scholar
• Ayele B, Gebre T, House JI et al. Adverse events after mass azithromycin treatments for trachoma in Ethiopia. Am. J. Trop. Med. Hyg.85, 291–294 (2011).
   PubMed Web of Science ®Google Scholar
• Batt SL, Charalambous BM, Solomon AW et al. Impact of azithromycin administration for trachoma control on the carriage of antibiotic-resistant Streptococcus pneumoniae. Antimicrob. Agents Chemother.47, 2765–2769 (2003).
   PubMed Web of Science ®Google Scholar
• Gaynor BD, Holbrook KA, Whitcher JP et al. Community treatment with azithromycin for trachoma is not associated with antibiotic resistance in Streptococcus pneumoniae at 1 year. Br. J. Ophthalmol.87, 147–148 (2003).
   PubMed Web of Science ®Google Scholar
• Skalet AHCV, Ayele B, Gebre T et al.Antibiotic selection pressure and macrolide resistance in nasopharyngeal Streptococcus pneumoniae: a cluster-randomized clinical trial. PLoS Med.7, e1000377 (2010).
   PubMed Web of Science ®Google Scholar
• Gaynor BD, Chidambaram JD, Cevallos V et al. Topical ocular antibiotics induce bacterial resistance at extraocular sites. Br. J. Ophthalmol.89, 1097–1099 (2005).
   PubMed Web of Science ®Google Scholar
• Bhengraj ARVH, Srivastava P, Salhan S, Mittal A. Decreased susceptibility to azithromycin and doxycycline in clinical isolates of Chlamydia trachomatis obtained from recurrently infected female patients in India. Chemotherapy56, 371–377 (2010).
   PubMed Web of Science ®Google Scholar
• West SK, West ES, Alemayehu W et al. Single-dose azithromycin prevents trichiasis recurrence following surgery: randomized trial in Ethiopia. Arch. Ophthalmol.124, 309–314 (2006).
   PubMed Web of Science ®Google Scholar
• Holm SO, Jha HC, Bhatta RC et al. Comparison of two azithromycin distribution strategies for controlling trachoma in Nepal. Bull. World Health Organ.79, 194–200 (2001).
   PubMed Web of Science ®Google Scholar
• Frick KD, Lietman TM, Holm SO, Jha HC, Chaudhary JS, Bhatta RC. Cost–effectiveness of trachoma control measures: comparing targeted household treatment and mass treatment of children. Bull. World Health Organ.79, 201–207 (2001).
   PubMed Web of Science ®Google Scholar
• Ssemanda EN, Munoz B, Harding-Esch EM et al. Mass treatment with azithromycin for trachoma control: participation clusters in households. PLoS Negl. Trop. Dis.4(10), pii: e838 (2010).
   Google Scholar
• Melese M, Alemayehu W, Lakew T et al. Comparison of annual and biannual mass antibiotic administration for elimination of infectious trachoma. JAMA299, 778–784 (2008).
   PubMed Web of Science ®Google Scholar
• Burton MJ, Holland MJ, Makalo P et al. Re-emergence of Chlamydia trachomatis infection after mass antibiotic treatment of a trachoma-endemic Gambian community: a longitudinal study. Lancet365, 1321–1328 (2005).
   PubMed Web of Science ®Google Scholar
• West SK, Munoz B, Mkocha H, Gaydos C, Quinn T. Trachoma and ocular Chlamydia trachomatis were not eliminated three years after two rounds of mass treatment in a trachoma hyperendemic village. Invest. Ophthalmol. Vis. Sci.48, 1492–1497 (2007).
   PubMed Web of Science ®Google Scholar
• Lakew T, House J, Hong KC et al. Reduction and return of infectious trachoma in severely affected communities in ethiopia. PLoS Negl. Trop. Dis.3, e376 (2009).
   PubMed Web of Science ®Google Scholar
• Cajas-Monson LC, Mkocha H, Muñoz B, Quinn TC, Gaydos CA, West SK. Risk factors for ocular infection with Chlamydia trachomatis in children 6 months following mass treatment in Tanzania. PLoS Negl. Trop. Dis.5, e978 (2011).
   PubMed Web of Science ®Google Scholar
• West SK, Stare D, Mkocha H, Munoz B, Gaydos C, Quinn TC. Do infants increase the risk of re-emergent infection in households after mass drug administration for trachoma? Invest. Ophthalmol. Vis. Sci.52(8), 6040–6042 (2011).
   PubMed Web of Science ®Google Scholar
• Campbell JP, Mkocha H, Munoz B, West SK. Randomized trial of high dose azithromycin compared to standard dosing for children with severe trachoma in Tanzania. Ophthalmic. Epidemiol.16, 175–180 (2009).
   PubMed Web of Science ®Google Scholar
• West SK, Munoz B, Mkocha H, Gaydos C, Quinn T. Number of years of annual mass treatment with azithromycin needed to control trachoma in hyper-endemic communities in Tanzania. J. Infect. Dis.204, 268–273 (2009).
   Google Scholar
• Frick KD, West SK. The SAFE strategy for trachoma control: planning a cost-effectiveness analysis of the antibiotic component and beyond. Ophthalmic Epidemiol.8, 205–214 (2001).
   PubMedGoogle Scholar
• Solomon AW, Akudibillah J, Abugri P et al. Pilot study of the use of community volunteers to distribute azithromycin for trachoma control in Ghana. Bull. World Health Organ.79, 8–14 (2001).
   PubMedGoogle Scholar
• Lynch M, West S, Frick K, Mkocha H. Azithromycin treatment coverage in Tanzanian children using community volunteers. Ophthalmic Epidemiol.10, 167–175 (2003).
   PubMed Web of Science ®Google Scholar
• Basilion EV, Kilima PM, Mecaskey JW. Simplification and improvement of height-based azithromycin treatment for paediatric trachoma. Trans. R. Soc. Trop. Med. Hyg.99, 6–12 (2005).
   PubMed Web of Science ®Google Scholar
• Hotez PJ, Molyneux DH, Fenwick A et al. Control of neglected tropical diseases. N. Engl. J. Med.357, 1018–1027 (2007).
   PubMedGoogle Scholar
• Linehan MCHC, Weaver A, Baker M et al. Integrated implementation of programs targeting neglected tropical diseases through preventive chemotherapy: proving the feasibility at national scale. Am. J. Trop. Med. Hyg.84, 5–14 (2011).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Report of the first meeting of WHO strategic and technical advisory group on neglected tropical diseases. World Health Organization, Geneva, Switzerland (2007).
   Google Scholar
• Koukounari ATS, Donnelly CA, Ouedraogo A et al. Integrated monitoring and evaluation and environmental risk factors for urogenital schistosomiasis and active trachoma in Burkina Faso before preventative chemotherapy using sentinel sites. BMC Infect. Dis.11, 191 (2011).
   PubMedGoogle Scholar